Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Gemcitabine plus carboplatin in recurrent or metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. gemcitabine in combination with capecitabine is also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Treatments: Capecitabine; Carboplatin; Gemcitabine

Criteria

Inclusion Criteria:

• Female

• 18-70 years old

• ECOG 0-1

• Expected lifetime more than 12 weeks

Exclusion Criteria:

• Pregnancy

• Brain Metastasis,

• Severe Infection